Paclitaxel, Carboplatin, and Bevacizumab Treatment in Gynecologic Cancers
In this article
Carboplatin + Paclitaxel + Bevacizumabis used mainly in epithelial ovarian cancer, selected advanced/recurrent endometrial cancer and persistent/recurrent/metastatic cervical cancer as a conventional chemotherapy + targeted therapy combination. The standard platinum–taxane regimen is supplemented with bevacizumab, an anti-VEGF monoclonal antibody that inhibits tumor blood-vessel formation.
In ovarian cancer, the combination demonstrated, particularly in GOG-0218 and ICON7 phase 3 trials, and in cervical cancer in GOG-240 , that adding bevacizumab to chemotherapy produces significant improvements in progression-free and/or overall survival . Endometrial cancer data are more limited and include phase 2 randomized studies such as MITO END-2 , with a snowball effect.
- Indications (summary):
- Ovarian: Advanced-stage (FIGO III–IV) epithelial ovarian, fallopian tube, and primary peritoneal cancer—first line.
- Endometrial: Selected advanced or recurrent cases scheduled for chemotherapy (off-label / trial data).
- Cervical: Persistent, recurrent, or metastatic cervical cancer—with platinum + paclitaxel; many protocols allow either cisplatin or carboplatin.
- Typical schedule: combination every 3 weeks, followed by bevacizumab maintenance for ovarian/cervical cancer.
- Chemotherapy-related hematologic toxicity, neuropathy, and alopecia.
- Bevacizumab-related hypertension, proteinuria, thromboembolism, and rare gastrointestinal perforation.
- Requires close follow-up, comorbidity management, and dose modification when necessary.
- Prolong DFS/PFS and delay recurrence.
- Reduce tumor burden and control symptoms.
- Improve long-term survival alongside surgery in ovarian/endometrial cancer; prolong survival in advanced/palliative cervical cancer.
Main Indications: Ovarian, Endometrial, Cervical
1. Ovarian Cancer (Epithelial Ovarian, Fallopian Tube, Primary Peritoneal)
According to current guidelines, carboplatin + paclitaxel + bevacizumab in ovarian cancer is mainly considered in newly diagnosed advanced-stage (FIGO III–IV) epithelial ovarian cancer as a first-line systemic treatment option. It is particularly strong for:
- Patients after primary or interval cytoreduction with suboptimal residual tumor,
- Stage IV, bulky intra-abdominal disease, or nodal/distant metastases,
- Patients whose organ function and performance status allow them to tolerate the combination
.
2. Endometrial Cancer (Advanced / Recurrent)
Standard chemotherapy for endometrial cancer is carboplatin + paclitaxel ; evidence for adding bevacizumab comes from smaller studies, particularly MITO END-2 and other phase 2 trials. Therefore:
- In selected advanced or recurrent cases scheduled for chemotherapy,
- Particularly with high tumor burden or a prominent vascular component,
- Taking patient and center experience, cost, and reimbursement into account,
off-label / outside-guideline use may be considered. Shared patient-physician decision-making and ethics committee/off-label approval processes are important.
3. Cervical Cancer (Persistent / Recurrent / Metastatic)
In cervical cancer, GOG-240 identified bevacizumab added to platinum + paclitaxel chemotherapy as the first targeted therapy to prolong overall survival in persistent, recurrent, or metastatic disease .
- Pelvic recurrence, distant metastases, or persistent disease after radiotherapy,
- Good performance status and adequate organ function,
- Low risk of gastrointestinal perforation and serious bleeding
characterize suitable patients. The platinum component may be cisplatin or carboplatin ; carboplatin is used in this account to align with the ovarian/endometrial regimen.
Comparison With Standard Platinum–Taxane Treatment
Suitable and Higher-Risk Patient Profiles
- Patients with ECOG 0–1 performance status who can tolerate systemic treatment.
- Advanced or recurrent ovarian/endometrial cancer, or persistent/recurrent/metastatic cervical cancer.
- Controlled hypertension without a history of major cardiovascular events.
- Minimal or no proteinuria, with a low risk of gastrointestinal perforation.
- Severe uncontrolled hypertension, recent stroke, or a history of major cardiovascular events.
- Significant proteinuria, impaired kidney function, or recurrent thromboembolism.
- Recent major surgery (<~28 days) with incomplete wound healing.
- Previous gastrointestinal perforation or severe GI ulceration/colitis, with a high fistula risk.
Carboplatin
Carboplatin is a platinum-derived alkylating agent that forms intrastrand and interstrand DNA cross-links, disrupting replication and transcription and ultimately causing apoptosis . It is generally less nephrotoxic and emetogenic than cisplatin but has a marked myelosuppressive effect.
- Dosing is usually AUC-based and calculated from GFR using the Calvert formula.
- Neutropenia and thrombocytopenia are the main dose-limiting adverse effects.
Paclitaxel
Paclitaxel is a taxane-class microtubule-stabilizing agent. It stabilizes microtubules, prevents depolymerization, and disrupts mitotic spindle formation, causing G2/M phase arrest.
- Dose-dependent effects include peripheral neuropathy, alopecia, myelosuppression, and hypersensitivity reactions.
- Premedication with steroids and antihistamines is required to reduce hypersensitivity risk.
Bevacizumab
Bevacizumab binds to vascular endothelial growth factor (VEGF-A)and blocks its interaction with its receptor. It is a recombinant humanized monoclonal antibody.
- By reducing neoangiogenesis and tumor-vessel permeability, it aims to suppress tumor growth and metastasis.
- Its main adverse effects include hypertension, proteinuria, thromboembolic events, and wound-healing problems and, rarely, gastrointestinal perforation .
1. Ovarian Cancer (GOG-0218, ICON7, and Others)
The two pivotal phase 3 trials evaluating carboplatin + paclitaxel + bevacizumab in first-line ovarian cancer were GOG-0218 and ICON7. These studies found:
- Starting bevacizumab with chemotherapy and continuing it alone as maintenance produced, compared with platinum–taxane chemotherapy, significantly longer progression-free survival .
- Benefit was greater in high-risk advanced-stage subgroups with suboptimal residual disease or stage IV disease.
- Toxicity is predictable and can be managed with appropriate patient selection and close follow-up.
2. Endometrial Cancer (MITO END-2 and Selected Data)
MITO END-2 phase 2 compared, in advanced or recurrent endometrial cancer, carboplatin + paclitaxel with the same regimen plus bevacizumab ; with generally tolerable additional toxicity, signals of improved response and PFS were reported. However:
- This is phase 2 evidence; no confirmatory phase 3 data are available.
- It is not a standard guideline option and is mainly discussed off-label for selected cases .
3. Cervical Cancer (GOG-240 and Real-World Data)
GOG-240 phase 3 showed that, in persistent/recurrent/metastatic cervical cancer, adding bevacizumab to platinum + paclitaxel chemotherapy, compared with chemotherapy alone, significantly prolonged overall survival , making bevacizumab a standard targeted agent in this population.
- Either cisplatin or carboplatin may be used as the platinum, with no significant survival difference observed.
- Real-world studies from Türkiye, including metastatic/recurrent cervical cancer cohorts, also reported that chemotherapy + bevacizumab was effective and tolerable.
A standard schedule for ovarian and endometrial cancer, and GOG-240-like cervical cancer protocols, every 3 weeks (every 21 days) can be summarized as follows:
- Day 1
- Paclitaxel: 175 mg/m² by intravenous infusion over approximately 3 hours.
- Carboplatin: AUC 5–6, calculated with the Calvert formula, by IV infusion.
- Bevacizumab: 7.5-15 mg/kg IV infusion; may start with chemotherapy or be added after the first cycle in some protocols.
- Number of cycles: Usually 6 cycles every 3 weeks for ovarian and cervical cancer; endometrial schedules vary by patient and center practice.
- Maintenance treatment: After chemotherapy, bevacizumab may continue every 3 weeks as maintenance to complete a total treatment duration of approximately 12–15 months for ovarian and cervical cancer.
- For paclitaxel: To reduce hypersensitivity risk, use premedication containing a corticosteroid, H1 blocker, and H2 blocker .
- For bevacizumab: A longer first infusion of approximately 90 minutes may be followed by shorter infusions according to tolerability.
- Pretreatment assessment: Review blood-pressure control, urine protein screening, complete blood count, kidney and liver function, thromboembolism history, and wound healing.
A. Common Adverse Effects
- Hematologic: Neutropenia, anemia, thrombocytopenia; rarely febrile neutropenia.
- Neurological: Paclitaxel-related peripheral neuropathy: numbness, burning, or loss of sensation in the hands and feet.
- General: Fatigue, alopecia, nausea–vomiting, mucositis.
- Bevacizumab-related: Hypertension, proteinuria, headache.
B. Serious / Potentially Life-Threatening Adverse Effects
- GI perforation or fistula: Sudden severe abdominal pain, fever, signs of peritonitis.
- Severe hypertension: Treatment-resistant high blood pressure, hypertensive crisis.
- Thromboembolic events: Deep vein thrombosis, pulmonary embolism, stroke.
- Severe proteinuria / nephrotic syndrome: Marked edema, nephrotic-range protein loss.
- Severe myelosuppression: Grade 3–4 neutropenia, febrile neutropenia, severe thrombocytopenia.
C. Management Strategies
- Hematologic toxicity: Cycle delays, carboplatin/paclitaxel dose reduction, G-CSF prophylaxis in high-risk patients, and red-cell/platelet transfusions when needed.
- Neuropathy: Reduce paclitaxel or interrupt treatment; consider stopping paclitaxel if neuropathy progresses.
- Hypertension: Optimize antihypertensive treatment; extend the bevacizumab dosing interval or stop it for persistent or severe hypertension.
- Proteinuria: Regular urine protein monitoring; temporarily or permanently stop bevacizumab for significant proteinuria.
- Suspected GI perforation: Emergency surgical and multidisciplinary assessment; permanently stop bevacizumab.
Dose adjustments in carboplatin + paclitaxel + bevacizumab are based on hematologic parameters, organ function, toxicity grades and bevacizumab-specific risks.
| Condition / Toxicity | Recommended Approach (General Framework) |
|---|---|
| Grade 3–4 nonfebrile neutropenia or severe thrombocytopenia | Delay the next cycle; after blood counts recover, consider reducing carboplatin and/or paclitaxel by approximately 20% . Plan G-CSF prophylaxis if recurrent. |
| Febrile neutropenia | Begin emergency evaluation and broad-spectrum antibiotics; after neutropenia resolves, consider a substantial chemotherapy dose reduction and routine G-CSF prophylaxis. |
| Grade 2–3 peripheral neuropathy (paclitaxel-related) | Reduce paclitaxel gradually; if neuropathy progresses or substantially affects daily life, stop paclitaxel and, if necessary, change to carboplatin + bevacizumab or another protocol. |
| Severe uncontrolled hypertension | Intensify antihypertensive treatment; until blood pressure is controlled, temporarily withhold bevacizumab. It may be permanently discontinued if the problem persists. |
| Proteinuria >2 g/24 hours | Temporarily stop bevacizumab; decide on restarting or permanent discontinuation according to kidney function and proteinuria. |
| GI perforation, fistula, or serious bleeding | Bevacizumab is permanently discontinued; surgery and intensive supportive treatment are required. Reassess continued chemotherapy according to the patient's condition. |
| Marked deterioration in overall performance status (e.g., ECOG ≥2) | Review regimen intensity; consider fewer agents, less intensive schedules, maintenance alone, or palliative care. |
Carboplatin + paclitaxel + bevacizumab is used in ovarian, endometrial, and cervical cancers for selected patients as a potent chemotherapy + targeted therapy combination. The goals are to shrink the tumor, delay regrowth of the disease and prolong survival.
Treatment is usually given every 3 weeks ; after several chemotherapy cycles, some patients may continue with bevacizumab alone as maintenance treatment for a further period.
During this process:
- Fatigue, hair loss, nausea, low blood counts,
- Numbness/tingling in hands and feet,
- Increased blood pressure, increased urine protein
may occur. Sudden shortness of breath, chest pain, severe abdominal pain, high fever, or uncontrolled hypertension require medical attention without delay .
- Carboplatin and paclitaxel have long been used in Türkiye as standard chemotherapy agents.
- For established indications, including ovarian, endometrial, and cervical cancers, these medicines are generally listed in the SUT and reimbursed by SGK .
- Dose and usage conditions may vary by indication and SUT provision; each center should perform its own Medula/SUT checks.
- Although bevacizumab is licensed for multiple cancers in Türkiye, Altuzan/Avastin brand products are not routinely reimbursed by SGK for gynecologic oncology indications. However, other equivalent products are covered for certain indications.
- For reimbursed indications, see: https://www.drozdogan.com/bevasizumab-altuzan-zirabev-nedir-hangi-kanserin-tedavisinde-kullanilir-yan-etkileri/
Carboplatin + paclitaxel + bevacizumab is, in ovarian and cervical cancer, supported by large phase 3 trials; in endometrial cancer, evidence is limited to phase 2. It is an intensive but rational form of combination treatment.
However, the combination's toxicity burden, bevacizumab-specific risks, and SGK reimbursement restrictions in Türkiye make the following critical:
- Appropriate patient selection,
- Close monitoring for hypertension, proteinuria, and thromboembolism,
- Timely dose modifications when necessary,
- Oncology, surgical, cardiology, nephrology, and, when needed, legal/social-service support within a multidisciplinary approach
are critical to treatment success. Giving patients information about treatment goals, adverse effects, and possible financial/administrative processes in a transparent, detailed information manner may improve both adherence and quality of life.
- Perren TJ, et al. A Phase 3 Trial of Bevacizumab in Ovarian Cancer (ICON7). N Engl J Med; with the relevant year and volume/issue information.
- Burger RA, et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer (GOG-0218). N Engl J Med; with the relevant year and volume/issue information.
- Daniele G, et al. Bevacizumab, carboplatin, and paclitaxel in the first-line treatment of advanced ovarian cancer: multicenter experiences.
- Lorusso D, et al. MITO END-2: Carboplatin–Paclitaxel compared to Carboplatin–Paclitaxel–Bevacizumab in advanced or recurrent endometrial cancer. Gynecol Oncol 2019;155(3):406-412.
- Tewari KS, et al. Improved Survival with Bevacizumab in Advanced Cervical Cancer (GOG-240). N Engl J Med 2014;370:734-743.
- Godoy-Ortiz A, et al. Bevacizumab for recurrent, persistent or advanced cervical cancer: review of clinical evidence.
- Ercelep Ö, et al. Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer. Turk J Obstet Gynecol 2020;17(2):123-127.
- NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer / Endometrial Carcinoma / Cervical Cancer. Current versions.
- ESMO Clinical Practice Guidelines: Newly diagnosed and relapsed epithelial ovarian carcinoma; Endometrial cancer; Cervical cancer.
- T.C. Sosyal Güvenlik Kurumu (SGK). Sağlık Uygulama Tebliği (SUT) ve “Geri Ödeme Listeleri”. Current online access.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.